“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.
“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.
Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
"With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness," write Navid Leelani, DO, and Scott D. Lundy, MD, PhD.
“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.
Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient’s cancer, which may influence choice of treatment based on cancer stage and type.
"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.
Combining the antibody-drug conjugates sacituzumab govitecan and enfortumab vedotin was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.
In this installment, expert Paul E. Dato, MD, discusses the value of a multidisciplinary team in managing patients with mCRPC and considers how his institution ensures patients receive best available therapy.
"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.